SCHEMBL4756340

SCHEMBL4756340

NC(=O)c1ccc([C]=O)nc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.60
NNMT P40261 4/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
KDM4E B2RXH2 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
F7 P08709 1/20 0.42
F3 P13726 1/20 0.42
SARM1 Q6SZW1 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT6 Q8N6T7 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
SIRT4 Q9Y6E7 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
HPGDS O60760 1/20 0.41
MYC P01106 1/20 0.39
VNN1 O95497 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4271680 0.84 GRM5 (0.60) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL1993840 0.82 GRM5 (0.58) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL5163246 0.82 P4HA1 (0.57) GRM5
SCHEMBL4265444 0.77 GRM5 (0.60) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL4755076 0.76 MAPK1 (0.61) GRM5KDM4EL3MBTL1HPGDS
SCHEMBL19581478 0.74 NNMT (0.65) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL31196295 0.72 NNMT (0.63) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL978974 0.72 NNMT (0.63) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
6-Aminonicotinamide SCHEMBL105510 0.72 NNMT (1.00) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1
SCHEMBL447959 0.72 NNMT (0.63) GRM5NNMTSMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO claimed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US claimed
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR GRM5 266/4885NNMT 2568/4885SMN1; SMN2 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.